Search

Your search keyword '"Campion, Loïc"' showing total 22 results
Start Over Author "Campion, Loïc" Language undetermined
22 results on '"Campion, Loïc"'

1. Additional file 3 of The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability

Author

Derrien, Jennifer, Guérin-Charbonnel, Catherine, Gaborit, Victor, Campion, Loïc, Devic, Magali, Douillard, Elise, Roi, Nathalie, Avet-Loiseau, Hervé, Decaux, Olivier, Facon, Thierry, Mallm, Jan-Philipp, Eils, Roland, Munshi, Nikhil C., Moreau, Philippe, Herrmann, Carl, Magrangeas, Florence, and Minvielle, Stéphane

Abstract

Additional file 3 Figures S1–S30. Supplementary figures.

Published
2021
Full Text
View/download PDF

2. Additional file 3 of DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma

Author

Jean-Baptiste Alberge, Magrangeas, Florence, Wagner, Mirko, Denié, Soline, Guérin-Charbonnel, Catherine, Campion, Loïc, Attal, Michel, Avet-Loiseau, Hervé, Carell, Thomas, Moreau, Philippe, Minvielle, Stéphane, and Sérandour, Aurélien A.

Abstract

Additional file 3. Methods: This file describes normal plasma cells purification, myeloma cells purification, 5mC and 5hmC dosage by mass spectrometry, bioinformatics methods and statistical analysis.

Published
2020
Full Text
View/download PDF

3. Additional file 2 of DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma

Author

Jean-Baptiste Alberge, Magrangeas, Florence, Wagner, Mirko, Denié, Soline, Guérin-Charbonnel, Catherine, Campion, Loïc, Attal, Michel, Avet-Loiseau, Hervé, Carell, Thomas, Moreau, Philippe, Minvielle, Stéphane, and Sérandour, Aurélien A.

Abstract

Additional file 2. Table S1: Patients characteristics, survival and mass spectrometry quantification of 5hmC and 5mC. Table S2: Scoring of 1816 5hmC-enriched domains across NDMM samples. Table S3: Motif analysis of core regulatory circuitries. Table S4: Scoring of groups-specific 5hmC-enriched domains. Table S5: Differential 5hmC-enriched domains between at diagnosis and relapse (DiffBind analysis).

Published
2020
Full Text
View/download PDF

4. Additional file 6: of Gene-expression signature functional annotation of breast cancer tumours in function of age

Author

Jézéquel, Pascal, Sharif, Zein, Lasla, Hamza, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Campion, Loïc, Chrétien, Stéphane, and Campone, Mario

Abstract

GO biological process enrichment analyses of most differentially expressed genes between AG1 and AG3. Head of columns represents SAM gene lists used as ToppGene inputs. The ten first significant biological processes are displayed (cutoff p-value = 0.01). (PDF 45 kb)

Published
2015
Full Text
View/download PDF

10. Additional file 2: of Gene-expression signature functional annotation of breast cancer tumours in function of age

Author

Jézéquel, Pascal, Sharif, Zein, Lasla, Hamza, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Campion, Loïc, Chrétien, Stéphane, and Campone, Mario

Subjects
musculoskeletal diseases, congenital, hereditary, and neonatal diseases and abnormalities, animal structures, macromolecular substances, skin and connective tissue diseases
Abstract

Metastasis-free survival (MFS) and overall survival (OS) analyses. MFS: 2A1: whole cohort; 2A2: Caucasian cohort. OS: 2B1: whole cohort; 2B2: Caucasian cohort. (PDF 230 kb)

Published
2015
Full Text
View/download PDF

12. Additional file 2: of Gene-expression signature functional annotation of breast cancer tumours in function of age

Author

Jézéquel, Pascal, Sharif, Zein, Lasla, Hamza, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Campion, Loïc, Chrétien, Stéphane, and Campone, Mario

Subjects
musculoskeletal diseases, congenital, hereditary, and neonatal diseases and abnormalities, animal structures, macromolecular substances, skin and connective tissue diseases
Abstract

Metastasis-free survival (MFS) and overall survival (OS) analyses. MFS: 2A1: whole cohort; 2A2: Caucasian cohort. OS: 2B1: whole cohort; 2B2: Caucasian cohort. (PDF 230 kb)

Published
2015
Full Text
View/download PDF

17. Additional file 6: of Gene-expression signature functional annotation of breast cancer tumours in function of age

Author

Jézéquel, Pascal, Sharif, Zein, Lasla, Hamza, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Campion, Loïc, Chrétien, Stéphane, and Campone, Mario

Abstract

GO biological process enrichment analyses of most differentially expressed genes between AG1 and AG3. Head of columns represents SAM gene lists used as ToppGene inputs. The ten first significant biological processes are displayed (cutoff p-value = 0.01). (PDF 45 kb)

Published
2015
Full Text
View/download PDF

18. Additional file 3: of Gene-expression signature functional annotation of breast cancer tumours in function of age

Author

Jézéquel, Pascal, Sharif, Zein, Lasla, Hamza, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Campion, Loïc, Chrétien, Stéphane, and Campone, Mario

Abstract

GES scoring of breast cancer in function of age. Correlation matrices show Pearson correlation coefficients between continuous GES (red indicates a positive correlation; blue, a negative correlation) and dendrograms show mutual relationships of all signatures (scores were used for average-link hierarchical clustering using the Pearson correlation as a distance metric). 2A1: AG1, whole cohort; 2A2: AG2, whole cohort; 2A3: AG3 whole cohort; 2B1: AG1, Caucasian cohort; 2B2: AG2, Caucasian cohort; 2B3: AG3, Caucasian cohort. (PDF 1689 kb)

Published
2015
Full Text
View/download PDF

20. Additional file 3: of Gene-expression signature functional annotation of breast cancer tumours in function of age

Author

Jézéquel, Pascal, Sharif, Zein, Lasla, Hamza, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Campion, Loïc, Chrétien, Stéphane, and Campone, Mario

Abstract

GES scoring of breast cancer in function of age. Correlation matrices show Pearson correlation coefficients between continuous GES (red indicates a positive correlation; blue, a negative correlation) and dendrograms show mutual relationships of all signatures (scores were used for average-link hierarchical clustering using the Pearson correlation as a distance metric). 2A1: AG1, whole cohort; 2A2: AG2, whole cohort; 2A3: AG3 whole cohort; 2B1: AG1, Caucasian cohort; 2B2: AG2, Caucasian cohort; 2B3: AG3, Caucasian cohort. (PDF 1689 kb)

Published
2015
Full Text
View/download PDF

21. First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients

Author

Maucherat, B., Leduc-Pennec, A., Fleury, N., Ferrer, Ludovic, Bourbouloux, E., Simon, H., Le Thiec, M., Rusu, D., Fleury, V., Colombie, M., Morel, A., Kraeber-Bodéré, Françoise, Campion, Loïc, Rousseau, Caroline, Service de médecine nucléaire [Saint-Herblain], Centre René Gauducheau-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER-Institut Régional du Cancer Nantes-Atlantique (IRCNA), Service de médecine nucléaire [Brest], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Morvan [Brest], Délégation à la recherche clinique [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Département de Physique [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Département d'Oncologie [Saint Herblain], Département de Radio-Oncologie [CHRU Brest], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Unité de Biométrie [ICO, Saint Herblain], Bernardo, Elizabeth, Centre René Gauducheau-Institut Régional du Cancer Nantes-Atlantique (IRCNA)-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; Aim/Introduction: About 70% of primitive breast cancers had positive estrogen receptors (ER) and may benefit from hormonotherapy. However, ER expression in breast cancer metastases is heterogeneous and about 15% of metastases lost this expression over time. Biopsies were not possible systematically. 16α-18Fluoro-17β-Oestradiol (18FES) is a radiopharmaceutical which predict the response to the first line hormonotherapy. The aim of this prospective study (NCT03442504) was to determine the predictive value of PET at the patient level, before a second line hormonotherapy (2nd- HT) on the FDG response obtained at 6 weeks of treatment. Materials and Methods: We prospectively included 12 ER+ metastatic breast cancer patients, HER2 negative, in progression despite first line hormonotherapy. For the complete study, 60 patients will be included. Due to 2nd-HT proposed by oncologist, we performed 18FES PET-CT (18FES-BL) and 18FDG PET-CT (18FDG-BL) at baseline in the month before the new treatment introduction. Follow-up with 18FDG PET-CT and CT

22. Between pathological prostate cancer lymph node and sentinel lymph node status : which one is the most informative ?

Author

Morel, A, Fleury, V, Le Thiec, M, Maucherat, B., Colombié, M, Rusu, D, Aillet, G, Kraeber-Bodéré, Françoise, Rousseau, T, Campion, Loïc, Rousseau, Caroline, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Institut d'Histopathologie [Nantes], Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), European-Association-of-Nuclear-Medicine (EANM), Bernardo, Elizabeth, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Catalog

Books, media, physical & digital resources
See catalog results